| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| chr11:59146668-59147484:+ | BLCA | EER | Monocytes | 1.5426e-02 | -0.4382 |  |
| ENSG00000166801.14,FAM111A | BLCA | EAG | Monocytes | 1.5426e-02 | -0.4382 |  |
| ENSG00000166801.14,FAM111A | BRCA | EAG | B_cells_naive | 3.1908e-02 | -0.1304 |  |
| chr11:59146668-59147484:+ | CESC | EER | Mast_cells_activated | 1.0255e-02 | -0.4169 |  |
| ENSG00000166801.14,FAM111A | CESC | EAG | Mast_cells_activated | 1.0255e-02 | -0.4169 |  |
| chr11:59146668-59147484:+ | COAD | EER | NK_cells_resting | 2.3917e-03 | -0.4562 |  |
| ENSG00000166801.14,FAM111A | COAD | EAG | NK_cells_resting | 2.3917e-03 | -0.4562 |  |
| chr11:59146668-59147484:+ | ESCA | EER | Macrophages_M0 | 1.0608e-04 | 0.3834 |  |
| ENSG00000166801.14,FAM111A | ESCA | EAG | Macrophages_M0 | 1.0258e-04 | 0.3841 |  |
| chr11:59146668-59147484:+ | KIRC | EER | T_cells_CD8 | 3.0458e-03 | 0.2813 |  |
| ENSG00000166801.14,FAM111A | KIRC | EAG | T_cells_CD8 | 3.0458e-03 | 0.2813 |  |
| chr11:59146668-59147484:+ | KIRP | EER | NK_cells_activated | 3.2646e-02 | -0.3728 |  |
| ENSG00000166801.14,FAM111A | KIRP | EAG | NK_cells_activated | 3.2646e-02 | -0.3728 |  |
| chr11:59146668-59147484:+ | LAML | EER | B_cells_memory | 1.7231e-02 | 0.2062 |  |
| ENSG00000166801.14,FAM111A | LAML | EAG | B_cells_memory | 1.4566e-02 | 0.2106 |  |
| chr11:59146668-59147484:+ | LUAD | EER | T_cells_gamma_delta | 1.3959e-02 | -0.2673 |  |
| ENSG00000166801.14,FAM111A | LUAD | EAG | T_cells_CD4_memory_resting | 1.7909e-02 | -0.2563 |  |
| chr11:59146668-59147484:+ | OV | EER | T_cells_regulatory_(Tregs) | 2.6179e-04 | 0.6284 | .chr11_59146668-59147484_+.png) |
| ENSG00000166801.14,FAM111A | OV | EAG | T_cells_regulatory_(Tregs) | 2.6179e-04 | 0.6284 | .ENSG00000166801.14,FAM111A.png) |
| chr11:59146668-59147484:+ | STAD | EER | Eosinophils | 3.0205e-03 | 0.2463 |  |
| ENSG00000166801.14,FAM111A | STAD | EAG | Eosinophils | 3.6270e-03 | 0.2409 |  |
| chr11:59146668-59147484:+ | THCA | EER | Dendritic_cells_activated | 1.8092e-02 | 0.2544 |  |
| ENSG00000166801.14,FAM111A | THCA | EAG | Dendritic_cells_activated | 1.8092e-02 | 0.2544 |  |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| chr11:59146668-59147484:+ | BLCA | GSVA_HALLMARK_TGF_BETA_SIGNALING | EER | 8.6722e-03 | -0.4706 |  |
| ENSG00000166801.14,FAM111A | BLCA | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 8.6722e-03 | -0.4706 |  |
| chr11:59146668-59147484:+ | BRCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 1.5785e-02 | -0.1471 |  |
| ENSG00000166801.14,FAM111A | BRCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 1.0884e-02 | -0.1545 |  |
| chr11:59146668-59147484:+ | CESC | GSVA_HALLMARK_G2M_CHECKPOINT | EER | 1.3842e-02 | -0.4012 |  |
| ENSG00000166801.14,FAM111A | CESC | GSVA_HALLMARK_G2M_CHECKPOINT | EAG | 1.3842e-02 | -0.4012 |  |
| ENSG00000166801.14,FAM111A | COAD | GSVA_HALLMARK_NOTCH_SIGNALING | EAG | 2.6577e-02 | 0.3421 |  |
| chr11:59146668-59147484:+ | COAD | GSVA_HALLMARK_NOTCH_SIGNALING | EER | 2.6577e-02 | 0.3421 |  |
| ENSG00000166801.14,FAM111A | ESCA | GSVA_HALLMARK_HYPOXIA | EAG | 4.6424e-04 | 0.3487 |  |
| chr11:59146668-59147484:+ | ESCA | GSVA_HALLMARK_HYPOXIA | EER | 4.8198e-04 | 0.3478 |  |
| ENSG00000166801.14,FAM111A | GBM | GSVA_HALLMARK_APOPTOSIS | EAG | 3.6887e-03 | 0.5693 |  |
| chr11:59146668-59147484:+ | GBM | GSVA_HALLMARK_APOPTOSIS | EER | 3.6887e-03 | 0.5693 |  |
| ENSG00000166801.14,FAM111A | KIRC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 6.7649e-03 | 0.2580 |  |
| chr11:59146668-59147484:+ | KIRC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 6.7649e-03 | 0.2580 |  |
| ENSG00000166801.14,FAM111A | KIRP | GSVA_HALLMARK_E2F_TARGETS | EAG | 2.7360e-03 | 0.5048 |  |
| chr11:59146668-59147484:+ | KIRP | GSVA_HALLMARK_E2F_TARGETS | EER | 2.7360e-03 | 0.5048 |  |
| ENSG00000166801.14,FAM111A | LAML | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 1.0036e-02 | -0.2217 |  |
| chr11:59146668-59147484:+ | LAML | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 1.0647e-02 | -0.2208 |  |
| ENSG00000166801.14,FAM111A | LUAD | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 3.1690e-02 | 0.2332 |  |
| chr11:59146668-59147484:+ | LUAD | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EER | 7.7307e-03 | 0.2887 |  |
| chr11:59146668-59147484:+ | LUSC | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.4556e-02 | 0.3620 |  |
| ENSG00000166801.14,FAM111A | LUSC | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.4556e-02 | 0.3620 |  |
| ENSG00000166801.14,FAM111A | OV | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EAG | 1.6376e-02 | -0.4420 |  |
| chr11:59146668-59147484:+ | OV | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 1.6376e-02 | -0.4420 |  |
| ENSG00000166801.14,FAM111A | STAD | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.9823e-03 | 0.2557 |  |
| chr11:59146668-59147484:+ | STAD | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 4.0223e-03 | 0.2391 |  |
| ENSG00000166801.14,FAM111A | THCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 1.4774e-03 | 0.3376 |  |
| chr11:59146668-59147484:+ | THCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 1.4774e-03 | 0.3376 |  |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| chr11:59146668-59147484:+ | BLCA | Methotrexate | EER | 7.1590e-03 | -0.4808 |  |
| ENSG00000166801.14,FAM111A | BLCA | Methotrexate | EAG | 7.1590e-03 | -0.4808 |  |
| chr11:59146668-59147484:+ | BRCA | KIN001.135 | EER | 5.9329e-03 | 0.1674 |  |
| ENSG00000166801.14,FAM111A | BRCA | KIN001.135 | EAG | 1.8126e-03 | 0.1887 |  |
| chr11:59146668-59147484:+ | CESC | BMS.536924 | EER | 4.1820e-03 | -0.4599 |  |
| ENSG00000166801.14,FAM111A | CESC | BMS.536924 | EAG | 4.1820e-03 | -0.4599 |  |
| ENSG00000166801.14,FAM111A | COAD | GNF.2 | EAG | 3.3537e-02 | -0.3287 |  |
| chr11:59146668-59147484:+ | COAD | GNF.2 | EER | 3.3537e-02 | -0.3287 |  |
| ENSG00000166801.14,FAM111A | ESCA | Imatinib | EAG | 5.0947e-03 | -0.2822 |  |
| chr11:59146668-59147484:+ | ESCA | Imatinib | EER | 5.0212e-03 | -0.2827 |  |
| ENSG00000166801.14,FAM111A | GBM | DMOG | EAG | 1.5648e-03 | -0.6096 |  |
| chr11:59146668-59147484:+ | GBM | DMOG | EER | 1.5648e-03 | -0.6096 |  |
| ENSG00000166801.14,FAM111A | KIRC | AP.24534 | EAG | 1.5804e-03 | 0.2991 |  |
| chr11:59146668-59147484:+ | KIRC | AP.24534 | EER | 1.5804e-03 | 0.2991 |  |
| ENSG00000166801.14,FAM111A | KIRP | Cisplatin | EAG | 1.1514e-02 | -0.4345 |  |
| chr11:59146668-59147484:+ | KIRP | Cisplatin | EER | 1.1514e-02 | -0.4345 |  |
| ENSG00000166801.14,FAM111A | LAML | JNK.9L | EAG | 3.4115e-02 | -0.1832 |  |
| chr11:59146668-59147484:+ | LAML | GSK.650394 | EER | 2.3890e-02 | -0.1958 |  |
| ENSG00000166801.14,FAM111A | LUAD | GW843682X | EAG | 3.5308e-03 | -0.3131 |  |
| chr11:59146668-59147484:+ | LUAD | CCT007093 | EER | 9.6125e-04 | 0.3538 |  |
| chr11:59146668-59147484:+ | LUSC | MG.132 | EER | 1.1250e-02 | -0.3745 |  |
| ENSG00000166801.14,FAM111A | LUSC | MG.132 | EAG | 1.1250e-02 | -0.3745 |  |
| ENSG00000166801.14,FAM111A | OV | Bortezomib | EAG | 1.8142e-04 | -0.6406 |  |
| chr11:59146668-59147484:+ | OV | Bortezomib | EER | 1.8142e-04 | -0.6406 |  |
| ENSG00000166801.14,FAM111A | STAD | Bexarotene | EAG | 4.5622e-03 | -0.2351 |  |
| chr11:59146668-59147484:+ | STAD | Bexarotene | EER | 5.6945e-03 | -0.2301 |  |
| ENSG00000166801.14,FAM111A | THCA | CEP.701 | EAG | 8.6852e-04 | 0.3526 |  |
| chr11:59146668-59147484:+ | THCA | CEP.701 | EER | 8.6852e-04 | 0.3526 |  |